Views: 123 Downloads: 27

Abstract

The goal of the current study was to determine if interleukin-10 (IL-10) promoter polymorphisms may predict how well Iraqi patients with rheumatoid arthritis (RA) will respond to etanercept (ETN). The trial was conducted at the Baghdad Teaching Hospital's rheumatology unit in Medical City, Baghdad, Iraq. Three IL-10 promoter single-nucleotide polymorphisms (SNPs) were genotyped for a cohort of ninety RA patients: rs1800871 (-824), rs1800872 (-597), and rs1800896 (-1082). The patients were clinically evaluated for ETN response at baseline, three, and six months after ETN therapy. Based on the Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR). The results demonstrated that the mutant G allele of rs1800896 was significantly more frequent among responders (45.2%) compared to non-responders (25.0%) (OR=0.40, 95% CI 0.21–0.77, p=0.0055). Binary logistic regression further confirmed the G allele's strong association with a positive outcome (OR=0.217, p=0.001). Additionally, patients with the AG genotype exhibited a significantly greater improvement in DAS28-ESR than others after six months (p=0.009). In conclusion, the IL-10 rs1800896 G allele is a promising predictive biomarker for a favorable response to ETN therapy in Iraqi RA patients‎.

Keywords: Pharmacogenetics, Polymorphism, IL-10, Etanercept, Anti-TNF, Rheumatoid arthritis

Citation Formats: